Preclinical evidence of neuroprotection by cholinesterase inhibitors.

Preclinical evidence of neuroprotection by cholinesterase inhibitors.

Item
http://www.wikidata.org/entity/Q36506190
Alpha7 nicotinic acetylcholine receptor agonist promotes retinal ganglion cell function via modulating GABAergic presynaptic activity in a chronic glaucomatous model.Nicotinic acetylcholine receptor signalling: roles in Alzheimer's disease and amyloid neuroprotection.The emergence of cognitive discrepancies in preclinical Alzheimer's disease: a six-year case study.Effects of thyroxine and donepezil on hippocampal acetylcholine content, acetylcholinesterase activity, synaptotagmin-1 and SNAP-25 expression in hypothyroid adult ratsProtection against Brain Atrophy by Anti-dementia Medication in Mild Cognitive Impairment and Alzheimer's Disease: Meta-Analysis of Longitudinal Randomized Placebo-Controlled TrialsBeyond symptomatic therapy: a re-examination of acetylcholinesterase inhibitors in Alzheimer's disease.Donepezil for Alzheimer's disease.An update on huperzine A as a treatment for Alzheimer's disease.Effects of donepezil on amyloid-beta and synapse density in the Tg2576 mouse model of Alzheimer's disease.Acute but not chronic donepezil increases muscarinic receptor-mediated signaling via arachidonic acid in unanesthetized rats.Cholinesterase Inhibitor Therapy in Alzheimer's Disease: The Limits and Tolerability of Irreversible CNS-Selective Acetylcholinesterase Inhibition in Primates.Revisiting choline alphoscerate profile: a new, perspective, role in dementia?Huprines for Alzheimer's disease drug development.New pharmacological approaches to the cholinergic system: an overview on muscarinic receptor ligands and cholinesterase inhibitors.Combined administration of cerebrolysin and donepezil induces plastic changes in prefrontal cortex in aged mice.Beyond symptomatic effects: potential of donepezil as a neuroprotective agent and disease modifier in Alzheimer's disease.
P2860

Preclinical evidence of neuroprotection by cholinesterase inhibitors.

Item
http://www.wikidata.org/entity/Q36506190
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
2006年论文
@zh
2006年论文
@zh-cn
name
Preclinical evidence of neuroprotection by cholinesterase inhibitors.
@ast
Preclinical evidence of neuroprotection by cholinesterase inhibitors.
@en
type
label
Preclinical evidence of neuroprotection by cholinesterase inhibitors.
@ast
Preclinical evidence of neuroprotection by cholinesterase inhibitors.
@en
prefLabel
Preclinical evidence of neuroprotection by cholinesterase inhibitors.
@ast
Preclinical evidence of neuroprotection by cholinesterase inhibitors.
@en
P1433
P1476
P2093
P304
P31
P356
P407
P433
P478
P577
P698
P356
P1433
P1476
Preclinical evidence of neuroprotection by cholinesterase inhibitors.
@en
P2093
P304
P31
P356
10.1097/01.WAD.0000213802.74434.D6
P407
P433
P478
P577
P698